Liquidia Corporation (LQDA)
The price, the headline numbers and the latest news, in one place.
Liquidia Corporation (LQDA) Stock Price, Analysis & Data
| Bid | 50.43 |
| Market Cap | 6.14B |
| Revenue (ttm) | 451M |
| Net Income (ttm) | 139M |
| 0.57 | |
| 1.4 | |
| 49.02 | |
| 12.15 | |
| P/B (ttm) | 31.34 |
| P/S (ttm) | 13.62 |
| Earnings Date | Nov 3, 2026 |
| Ask | 87.75 |
| Volume | 931,647 |
| Avg. Volume (20D) | 1,844,266 |
| Open | 69.27 |
| Previous Close | 69.68 |
| Day's Range | 68.15 - 70.75 |
| 52-Week Range | 21.15 - 93.61 |
| Analyst | Buy |
| Price Target | 109 (58.82%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprosti...
Financial Performance
In 2025, Liquidia's revenue was 158.32M, an increase of 1,031.18% compared to the previous year's 14M. Earnings were -68.92M, a decrease of -46.28%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for LQDA stock is "Buy". The 12-month stock price forecast is 109, which is upside of 58.82% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $132.87M misses estimates by $0, with 4158.49% YoY growth.
- EPS of 0.74 misses estimates by -0.10, with 251.02% YoY growth.
Analysts project revenue of ... Upgrade
